TABLE 1.
Susceptibility of wild-type and mutant ADA Envs to BMS-626529 and bNAbsa
| Antiviral | IC50 (nM) (fold change) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| WT | M426L | M434I | S375M | S375I | M475I | V506M | M426L/ M434I |
M426L/ M475I |
S375M/ M434I |
|
| BMS-626529 | 0.14 | 6.67 (49) | 0.26 (1.9) | 30.0 (221) | 1.78 (13.1) | 0.60 (4.4) | 0.11 (0.8) | 15.04 (111) | 5.81 (43) | 29.58 (218) |
| VRC03 | 0.18 | 0.16 (0.9) | 0.10 (0.6) | 0.08 (0.4) | 0.21 (1.2) | 0.09 (0.5) | 0.09 (0.5) | 0.107 (0.58) | 0.16 (0.9) | 0.11 (0.6) |
| VRC07-523 | 0.29 | 0.25 (0.8) | — | 0.16 (0.6) | — | — | — | — | — | 0.23 (0.8) |
| 4Dm2m | 0.06 | 0.08 (1.3) | 0.52 (8.1) | 0.03 (0.5) | 0.07 (1.1) | 0.73 (11) | 0.22 (3.5) | 0.373 (5.83) | 0.23 (3.8) | 0.05 (0.7) |
| 6Dm2m | 0.09 | 0.30 (3.2) | — | 0.06 (0.6) | — | — | — | — | — | 0.08 (0.8) |
| 35O22 | 0.06 | 0.15 (2.7) | 0.15 (2.5) | 0.05 (0.8) | 0.12 (2.0) | 0.13 (2.3) | 0.06 (1.1) | 0.06 (1.03) | 0.21 (3.5) | 0.12 (2.1) |
| PG16 | 0.08 | 0.08 (1.0) | — | 0.05 (0.6) | — | — | — | — | — | 0.06 (0.8) |
| PG16-iMab | 0.04 | 0.01 (0.2) | 0.01 (0.3) | 0.01 (0.4) | 0.01 (0.3) | 0.02 (0.6) | 0.02 (0.4) | 0.004 (0.10) | 0.03 (0.8) | 0.001 (0.0) |
| PGT128 | 0.09 | 0.03 (0.4) | 0.07 (0.7) | 0.02 (0.3) | 0.06 (0.6) | 0.11 (1.1) | 0.13 (1.4) | 0.076 (0.82) | 0.10 (1.2) | 0.04 (0.4) |
| PGT128-iMab | 0.02 | 0.01 (0.3) | 0.01 (0.4) | 0.01 (0.5) | 0.02 (0.8) | 0.02 (1.1) | 0.01 (0.7) | 0.001 (0.05) | 0.02 (0.9) | 0.004 (0.2) |
| NIH45-46G54W | 0.08 | 0.06 (0.7) | 0.09 (1.1) | 0.04 (0.5) | 0.06 (0.8) | 0.07 (0.8) | 0.07 (0.8) | 0.047 (0.56) | 0.13 (1.6) | 0.09 (1.1) |
| PG16-NIH45-46G54W | 0.03 | 0.03 (0.8) | 0.03 (0.9) | 0.03 (0.9) | 0.07 (2.1) | 0.04 (1.3) | 0.04 (1.2) | 0.03 (0.8) | 0.06 (1.6) | 0.12 (3.4) |
a
Data represent results of tests of GHOST-Hi5 cells with HIV-LIB pseudotyped viruses. Each entry shows the IC50 in nanomoles for the indicated strain; fold change in susceptibility compared to the WT is shown in parentheses. —, not determined.